Obesity May Strip Away a Natural Breast Cancer Defense
For years, researchers studying the link between obesity and breast cancer have asked how excess fat actively drives tumors. A new investigation from Huntsman Cancer Institute at the University of Utah flips that question, asking instead what protection disappears when body weight rises. The answer, published in the journal Science, centers on a fatty molecule that lean breast tissue produces in abundance and that obese tissue largely fails to supply.
The study was led by Keren Hilgendorf, Ph.D., an investigator at Huntsman Cancer Institute and an assistant professor of biochemistry at the University of Utah, who is the senior author. Meghan Curtin, a doctoral candidate in molecular biology at the university, is the first author. Their paper appears in Science under the DOI 10.1126/science.aea4287.
Hilgendorf characterized the result as a change in how the field might think about metabolic risk. Investigators have long examined the mechanisms by which obesity promotes disease, she noted, but had not seriously considered that obesity might also represent the absence of something the body uses to defend itself.
Fat Cells Are Active Players in Breast Tissue
Breasts consist mostly of fat, and the predominant cell type is the adipocyte. Rather than acting as passive storage, these fat cells define the immediate environment that neighboring cells — including cells on a path toward becoming cancerous — must contend with. Adipocytes are not uniform: their size and behavior shift with body weight. In lean individuals they remain relatively small, while in obesity they enlarge.
Lean and Obese Tissue Create Different Conditions
According to Hilgendorf, lean and obese adipocytes generate distinct microenvironments around cancer cells. Working with preclinical models, including breast tissue donated by human volunteers, she and Curtin pinpointed one of the most important divergences: the production of a lipid, or fatty acid, called 9S-HODE.
9S-HODE matters because of what it triggers. The molecule drives cells toward death, and specifically toward ferroptosis, a form of cell death the body uses to eliminate old and damaged cells. Cells that could otherwise develop into cancer fall into that category, which makes the lipid an important part of routine cellular housekeeping in the breast.
The Protective Molecule That Obesity Suppresses
The mechanism described in the study is unusual in that the protective agent is secreted. Mammary adipocytes release 9S-HODE into their surroundings, allowing the lipid to act on cells beyond the fat cell itself and suppress breast cancer growth from within the tissue. It is, in effect, a form of local tumor suppression that originates in fat.
Production is not equal across body types. The team found that lean adipocytes make far more 9S-HODE than obese adipocytes do. Curtin explained the consequence plainly: when the lipid is abundant, cancerous cells die more readily in lean tissue. In lean conditions, she said, the body is actively shielding itself through this molecule in a way that obesity does not permit.
The disparity in output — rather than any difference in how the lipid functions — appears to be the decisive factor. The protective pathway is not destroyed in obesity so much as starved of its key ingredient.
Can the Lost Protection Be Restored?
That framing points toward a therapeutic question. If the molecule is merely scarce rather than absent, supplying more of it might re-establish the safety signal. Hilgendorf and Curtin pursued exactly that line of inquiry in their preclinical mouse models, testing whether raising 9S-HODE levels in the obese setting could bring back the tumor-suppressing activity that lean tissue provides on its own.
The design of the study strengthens its translational relevance. Human donor breast tissue let the researchers observe how adipocytes from donors of different weights handle 9S-HODE production, while the mouse models offered a living system in which the pathway could be manipulated and observed. Together, the two approaches link a human-relevant observation to a testable intervention strategy.
This is a different therapeutic logic from the usual approach to obesity-related cancer risk. Rather than trying to neutralize a harmful signal generated by excess fat, an intervention built on this finding would aim to replace a beneficial signal that has been lost.
What the Research Does and Does Not Establish
The work identifies a pathway and a plausible explanation for part of obesity's association with breast cancer. It does not claim that obesity is the only factor shaping risk, nor that 9S-HODE levels alone determine whether a tumor develops. Several caveats are worth keeping in view:
- The findings rest on preclinical models, including mouse studies and donor tissue, and have not been validated in clinical trials involving patients.
- The study addresses a mechanism of risk, not a treatment; no clinical recommendation about 9S-HODE supplementation follows from it.
- Ferroptosis is one of several ways the body removes damaged cells, so this pathway is best understood as part of a broader system rather than a single switch.
- Adipocyte size and behavior vary across individuals and body weights, meaning the effect described is a general tendency rather than a fixed rule for any one person.
A Reframing of Obesity's Role in Cancer Risk
The study's most durable contribution may be conceptual. Obesity is typically described in cancer research as an active force — something that adds inflammatory signals, alters hormone levels, or otherwise pushes cells toward malignancy. This research suggests a complementary view: that excess fat also subtracts from the body's defenses, removing a lipid-based mechanism that would otherwise eliminate vulnerable cells.
For patients and clinicians, the distinction is more than semantic. A risk factor understood as an addition invites strategies that block or remove something. A risk factor understood as a loss invites strategies that restore. The finding from Huntsman Cancer Institute gives researchers a specific molecule, 9S-HODE, to work with in pursuing that second path.
Curtin's and Hilgendorf's results add to a growing body of work positioning fat tissue as an active regulator of cancer biology rather than a passive bystander. If further studies confirm that the 9S-HODE pathway can be replenished safely, the lipid could become a target for reducing breast cancer risk in people with obesity — a possibility that begins with recognizing what obesity takes away.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
